Literature DB >> 16618974

Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia.

Yutaka Harano1, Takeshi Miyawaki, Junko Nabiki, Miki Shibachi, Tomomi Adachi, Michiko Ikeda, Fukuhiro Ueda, Takamitsu Nakano.   

Abstract

A new cookie test was developed for the simultaneous evaluation of multiple risk factors such as glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. The cookie consisting of 75 g carbohydrate and 25 g fat is ingested and the blood samples are obtained at 0, 1 and 2 hours later. When the two carbohydrate sources, liquid glucose and test cookie, were compared as a glucose load within 3 months, the 2 hr plasma glucose levels were not statistically different, proposing the use of the same criteria at 2 hour glucose level for the diagnosis of diabetes and impaired glucose tolerance (IGT) in subjects without exocrine pancreatic dysfunction. In addition, hyperinsulinemia, insulin resistance (AUC insulin, and/or AUC insulin X AUC glucose), and postprandial hyperlipidemia (DeltaTG, Triglyceride; DeltaRLP, remnant like particles) have been simultaneously uncovered. Reactive hypoglycemia with adverse epigastric discomfort was observed in 26.3% of the control subjects with liquid glucose, while it was observed in only 1 case (5.3%) without any symptom with cookie tests. In fact, one reactive hypoglycemia out of 5 with liquid glucose turned out to be IGT with cookie test. In 64 subjects with lifestyle-related diseases, cookie test revealed hyperinsulinemia and insulin resistance in 56% respectively, postprandial hyperlipidemia in 39%, diabetes and IGT in 22-23% of each of the subjects and all showed at least one abnormal value. In contrast, in university students with exercise habit, all showed normal results with cookie test. In addition, improved insulin sensitivity over non-exercise group was obverved. In summary, the cookie test provided more informations compared with OGTT using liquid glucose and with fewer side effects. Simultaneous evaluation of glucose intolerance, hyperinsulinemia, insulin resistance, and postprandial hyperlipidemia was also possible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618974     DOI: 10.1507/endocrj.53.173

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  20 in total

1.  A hypertriglyceridemic state increases high sensitivity C-reactive protein of Japanese men with normal glucose tolerance.

Authors:  Kyoko Okada; Norihiro Furusyo; Masayuki Murata; Yasunori Sawayama; Mosaburo Kainuma; Jun Hayashi
Journal:  Endocrine       Date:  2011-09-24       Impact factor: 3.633

2.  Triglyceride metabolism in Japanese kidney transplant recipients.

Authors:  Makoto Tsujita; Norihiko Goto; Kenta Futamura; Manabu Okada; Takahisa Hiramitsu; Syunji Narumi; Yoshihiko Watarai
Journal:  Clin Exp Nephrol       Date:  2017-08-28       Impact factor: 2.801

3.  Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.

Authors:  Toru Kato; Teruo Inoue; Koichi Node
Journal:  Cardiovasc Diabetol       Date:  2010-03-24       Impact factor: 9.951

4.  Fasting Lipoprotein Lipase Protein Levels Can Predict a Postmeal Increment of Triglyceride Levels in Fasting Normohypertriglyceridemic Subjects.

Authors:  Kokoro Tsuzaki; Kazuhiko Kotani; Kazunori Yamada; Naoki Sakane
Journal:  J Clin Lab Anal       Date:  2015-08-24       Impact factor: 2.352

5.  Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report.

Authors:  Yoko Noda; Toru Miyoshi; Hiroki Oe; Yuko Ohno; Kazufumi Nakamura; Norihisa Toh; Kunihisa Kohno; Hiroshi Morita; Kengo Kusano; Hiroshi Ito
Journal:  Cardiovasc Diabetol       Date:  2013-01-09       Impact factor: 9.951

Review 6.  Immunometabolism in obese asthmatics: are we there yet?

Authors:  Hashim A Periyalil; Peter G Gibson; Lisa G Wood
Journal:  Nutrients       Date:  2013-09-10       Impact factor: 5.717

7.  Identification of differential responses to an oral glucose tolerance test in healthy adults.

Authors:  Ciara Morris; Colm O'Grada; Miriam Ryan; Helen M Roche; Michael J Gibney; Eileen R Gibney; Lorraine Brennan
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

Review 8.  Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.

Authors:  Jean-Charles Fruchart
Journal:  Cardiovasc Diabetol       Date:  2013-05-31       Impact factor: 9.951

9.  Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients.

Authors:  Takahiko Nagamine
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

10.  The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus.

Authors:  Faranak Sharifi; Nima Hojeghani; Saeideh Mazloomzadeh; Zahra Shajari
Journal:  J Diabetes Metab Disord       Date:  2013-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.